[go: up one dir, main page]

AU6179990A - Il-2 deletion mutants - Google Patents

Il-2 deletion mutants

Info

Publication number
AU6179990A
AU6179990A AU61799/90A AU6179990A AU6179990A AU 6179990 A AU6179990 A AU 6179990A AU 61799/90 A AU61799/90 A AU 61799/90A AU 6179990 A AU6179990 A AU 6179990A AU 6179990 A AU6179990 A AU 6179990A
Authority
AU
Australia
Prior art keywords
deletion mutants
mutants
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61799/90A
Inventor
Donna E. Akiyoshi
Francis S. Genbauffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seragen Inc
Original Assignee
Seragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seragen Inc filed Critical Seragen Inc
Publication of AU6179990A publication Critical patent/AU6179990A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU61799/90A 1989-08-02 1990-07-30 Il-2 deletion mutants Abandoned AU6179990A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US388557 1982-06-15
US38855789A 1989-08-02 1989-08-02

Publications (1)

Publication Number Publication Date
AU6179990A true AU6179990A (en) 1991-03-11

Family

ID=23534610

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61799/90A Abandoned AU6179990A (en) 1989-08-02 1990-07-30 Il-2 deletion mutants

Country Status (6)

Country Link
EP (1) EP0485497A4 (en)
JP (1) JPH04507250A (en)
AU (1) AU6179990A (en)
CA (1) CA2064696A1 (en)
NZ (1) NZ234674A (en)
WO (1) WO1991002000A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584251A4 (en) * 1991-05-17 1995-08-02 Seragen Inc Cytokine receptor targeted molecules for treatment of meoplastic cell growth.
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
EP1539960B1 (en) 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105722860A (en) * 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 Interleukin-2 fusion proteins and uses thereof
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
JP7165717B2 (en) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド target immune tolerance
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
CN111201035A (en) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Uses and methods of IL-2 superagonists, agonists and fusions thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP2022501009A (en) * 2018-09-21 2022-01-06 イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド New interleukin 2 and its use
US12269855B2 (en) 2018-09-21 2025-04-08 Innovent Biologics (Suzhou) Co., Ltd. Interleukin-2 and use thereof
CN114679909A (en) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM-targeted immune tolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
JP2023518443A (en) * 2020-03-19 2023-05-01 イノベント バイオロジクス(スーチョウ)カンパニー,リミティド Interleukin-2 mutants and uses thereof
WO2021185361A1 (en) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 Interleukin-2 mutant and use thereof
IL311643A (en) * 2021-09-22 2024-05-01 Fortvita Biologics Singapore Pte Ltd Interleukin-2 mutant and fusion protein thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii

Also Published As

Publication number Publication date
EP0485497A4 (en) 1992-07-08
EP0485497A1 (en) 1992-05-20
JPH04507250A (en) 1992-12-17
CA2064696A1 (en) 1991-02-03
WO1991002000A1 (en) 1991-02-21
NZ234674A (en) 1992-02-25

Similar Documents

Publication Publication Date Title
AU6179990A (en) Il-2 deletion mutants
AU2760088A (en) Solid lubricant composition
AU5348790A (en) Micro-multi-electrode arrangement
AU4473889A (en) Translation technique
AU4474189A (en) Translation technique
AR244339A1 (en) Subtilisin mutants
AU5748990A (en) Venoscope
AU5874690A (en) Octreotide-pamoate
AU4677089A (en) Chair
AU627080B2 (en) Sulphonylaminocarbonyltriazolinones
AU3396489A (en) Funzionalized fluoropolyethers
AU623262B2 (en) Hydroxypropylamines
AU631622B2 (en) Snow-vehicle
AU6627590A (en) Doll-container
AU5808490A (en) Vip-analogs 11
AU5600790A (en) Chromanderivate
AU5298490A (en) Ash classifier-cooler-combustor
AU5672790A (en) Protective coverings
AU4116189A (en) Lubricating composition
AU612915B2 (en) Thermosetting-resin-forming composition
AU6309890A (en) Stabilized leukocyte-interferons
AU5782590A (en) Thioxotetrazolines
AU5336690A (en) Leg-guard
AU6169990A (en) Biocontrol compositions
AU4944090A (en) Cryoelectrosynthesis